# DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML

> **NCT07712848** · PHASE3 · RECRUITING · sponsor: **The Second Affiliated Hospital of Kunming Medical University** · enrollment: 291 (estimated)

## Conditions studied

- AML (Acute Myeloid Leukemia)

## Interventions

- **PROCEDURE:** Arm A (VEN+"2+6"DA)
- **PROCEDURE:** Arm B (DEC3-VEN)
- **PROCEDURE:** Arm C ("3+7"DA)

## Key facts

- **NCT ID:** NCT07712848
- **Lead sponsor:** The Second Affiliated Hospital of Kunming Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 291 (ESTIMATED)
- **Last updated:** 2026-07-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07712848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07712848, "DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07712848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*